← All trials
NCT04275219
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2019
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Feb 19, 2020
- Last posted
- Feb 19, 2020
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou UniversityLead sponsor
- Dalian Medical UniversityCollaborator
- Ganzhou People's Hospital Affiliated to Nanchang UniversityCollaborator
- Lianjiang Hospital of Traditional Chinese MedicineCollaborator
- Yangjiang Hospital of Traditional Chinese MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.